

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

These amendments introduce no new matter and support for the amendment is replete throughout the specification and claims as originally filed. These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter, or agreement with any objection or rejection of record.

Listing of Claims:

1 (Currently Amended). A method of ~~preventing or treating an immune disorder in~~ a patient ~~in need thereof~~, which comprises:

selecting a patient in need of immune suppression; and,

administering to said patient an effective amount of an ~~IL-27R/WSX-1 ligand~~ IL-27R agonist.

2 (Cancelled).

3 (Currently Amended). The method of claim [2] 1, wherein said agonist is selected from the group consisting of IL-27, an active fragment of IL-27, and an agonistic antibody that enhances ~~IL-27R/WSX-1~~ IL-27R activity.

4-5 (Cancelled).

6 (Currently Amended). A method for ~~modulating~~ suppressing a T-helper cell mediated immune response in a patient in need thereof, which comprises administering to said patient an effective amount of an ~~IL-27R/WSX-1 ligand~~ IL-27R agonist.

7 (Cancelled).

8 (Currently Amended). The method of claim [7] 6, wherein said agonist is selected from the group consisting of IL-27, an active fragment of IL-27, and an agonistic antibody to ~~IL-27R/WSX-1~~ IL-27R which enhances ~~IL-27R/WSX-1~~ IL-27R activity.

9-10 (Cancelled).

11 (Previously Presented). The method of claim 6, wherein said T-helper cell is Th1.

12 (Previously Presented). The method of claim 6, wherein said T-helper cell is Th2.

13 (Currently Amended). A method for modulating an interferon- γ mediated immune response in a patient in need thereof, which comprises administering to said patient an effective amount of an ~~IL-27R/WSX-1 ligand~~ IL-27R agonist.

14 (Cancelled).

15 (Currently Amended). The method of claim [14] 13, wherein said agonist is selected from the group consisting of IL-27, an active fragment of IL-27, and an agonistic antibody to ~~IL-27R/WSX-1~~ IL-27R which enhances ~~IL-27R/WSX-1~~ IL-27R activity.

16-17 (Cancelled).

18 (Currently Amended). A method for treating immune hyperactivity in a ~~patient~~ patient in need thereof, which comprises administering to said patient an effective amount of an ~~IL-27R/WSX-1 ligand~~ IL-27R agonist.

19 (Currently Amended). A method for treating an immune hyperactivity disorder in a patient in need thereof, which comprises administering to said patient an effective amount of an ~~IL-27R/WSX-1 ligand~~ IL-27R agonist.

20 (Previously Presented). The method of claim 19, wherein said immune disorder is selected from the group consisting of autoimmune disorders, hypersensitivity disorders, allergies, and asthma.

21 (Currently Amended). The method of claim 20, wherein said immune disorder is selected from the group consisting of: Acquired Immune Deficiency Syndrome (AIDS); acute pancreatitis; Addison's disease; alcohol-induced liver injury; alcoholic cirrhosis; Alzheimer's disease; amyotrophic lateral sclerosis ~~amyelolaterosclerosis~~; asthma; pulmonary diseases; atherosclerosis; autoimmune vasculitis; autoimmune hepatitis-induced hepatic injury; biliary cirrhosis; cachexia/anorexia; AIDS-induced cachexia; cancer; multiple myeloma; leukemia; myelogenous leukemias; tumor metastasis; chronic fatigue syndrome; Clostridium associated illnesses; Clostridium-associated diarrhea; a coronary condition; a coronary indication; congestive heart failure; coronary restenosis; myocardial infarction;; myocardial dysfunction; a coronary artery bypass graft associated condition; diabetes; juvenile onset Type 1 diabetes; diabetes mellitus; insulin resistance; endometriosis; endometritis; endometriosis/endometritis related conditions; epididymitis; erythropoietin resistance; fever; fibromyalgia; analgesia; glomerulonephritis; graft versus host disease/transplant rejection; Graves' disease; Guillain-Barre syndrome; Hashimoto's disease; hemolytic anemia; hemorrhagic shock; hyperalgesia; inflammatory bowel disease; ulcerative colitis; Crohn's disease; an inflammatory conditions of a joint; rheumatic diseases osteoarthritis; rheumatoid arthritis; juvenile (rheumatoid) arthritis; seronegative polyarthritis; ankylosing spondylitis; Reiter's syndrome; reactive arthritis; Still's disease; psoriatic arthritis; enteropathic arthritis; polymyositis; dermatomyositis; scleroderma; systemic sclerosis; vasculitis; Kawasaki's disease; cerebral vasculitis; Lyme disease; staphylococcal-induced arthritis; Sjogren's syndrome; rheumatic fever; polychondritis; polymyalgia rheumatica; giant cell arteritis; inflammatory eye disease; corneal transplant associated

inflammatory eye disease; inflammatory bowel disease; ischemia; cerebral ischemia; Kawasaki's disease; learning impairment; lung disease; lupus nephritis; multiple sclerosis; myasthenia gravis; myopathyceneuroinflammatory disease; neurotoxicity; ocular diseases and conditions; ocular degeneration; uveitis; osteoporosis; pain; cancer-related pain; Parkinson's disease; pemphigus; periodontal disease; Pityriasis rubra pilaris; pre-term labor; prostatitis; a prostatitis related conditions; psoriasis; a psoriasis related conditions; psoriatic arthritis; pulmonary fibrosis; reperfusion injury; rheumatic fever; rheumatoid arthritis; sarcoidosis; scleroderma; septic shock; side effects from radiation therapy; Sjogren's syndrome; sleep disturbance; spondyloarthropathies; systemic lupus erythematosus; temporal mandibular joint disease; thyroiditis; tissue transplantation; an inflammatory condition resulting from strain; an inflammatory condition resulting from sprain; an inflammatory condition resulting from cartilage damage; an inflammatory condition resulting from trauma; an inflammatory condition resulting from orthopedic surgery; an inflammatory condition resulting from infection; transplant rejection; uveitis; and vasculitis.

22 (Currently Amended). A method for treating a T-helper cell mediated disorder in a patient in need thereof, which comprises administering to said patient an effective amount of an ~~IL-27R/WSX-1~~ ligand IL-27R agonist.

23 (Currently Amended). The method of claim 22, wherein said T-helper cell mediated disorder is selected from the group consisting of: Acquired Immune Deficiency Syndrome (AIDS); acute pancreatitis; Addison's disease; alcohol-induced liver injury; alcoholic cirrhosis; Alzheimer's disease; amyotrophic lateral sclerosis ~~amyelolaterosclerosis~~; asthma; pulmonary diseases; atherosclerosis; autoimmune vasculitis; autoimmune hepatitis-induced hepatic injury; biliary cirrhosis; cachexia/anorexia; AIDS-induced cachexia; cancer; multiple myeloma; leukemia; myelogenous leukemias; tumor metastasis; chronic fatigue syndrome; Clostridium associated illnesses; Clostridium-associated diarrhea; a coronary condition; a coronary indication; congestive heart failure; coronary restenosis; myocardial infarction; myocardial dysfunction; a coronary artery bypass graft associated condition; diabetes; juvenile onset Type 1 diabetes; diabetes mellitus; insulin resistance; endometriosis;

endometritis; an endometriosis/endometritis related conditions; epididymitis; erythropoietin resistance; fever; fibromyalgia; analgesia; glomerulonephritis; graft versus host disease/transplant rejection; Graves' disease; Guillain-Barre syndrome; Hashimoto's disease; hemolytic anemia; hemorrhagic shock; hyperalgesia; inflammatory bowel disease; ulcerative colitis; Crohn's disease; an inflammatory conditions of a joint; rheumatic diseases; osteoarthritis; rheumatoid arthritis; juvenile (rheumatoid) arthritis; seronegative polyarthritis; ankylosing spondylitis; Reiter's syndrome; and reactive arthritis; Still's disease; psoriatic arthritis; enteropathic arthritis; polymyositis; dermatomyositis; scleroderma; systemic sclerosis; vasculitis; Kawasaki's disease; cerebral vasculitis; Lyme disease; staphylococcal-induced arthritis; Sjogren's syndrome; rheumatic fever; polychondritis; polymyalgia rheumatica; giant cell arteritis; inflammatory eye disease; corneal transplant associated inflammatory eye disease; inflammatory bowel disease; ischemia; cerebral ischemia; Kawasaki's disease; learning impairment; lung diseases; lupus nephritis; multiple sclerosis; myasthenia gravis; myopathic neuroinflammatory diseases; neurotoxicity; ocular diseases and conditions; ocular degeneration; uveitis; osteoporosis; pain; cancer-related pain; Parkinson's disease; pemphigus; periodontal disease; Pityriasis rubra pilaris; pre-term labor; prostatitis; a prostatitis related conditions; psoriasis; a psoriasis related conditions; psoriatic arthritis; pulmonary fibrosis; reperfusion injury; rheumatic fever; rheumatoid arthritis; sarcoidosis; scleroderma; septic shock; side effects from radiation therapy; Sjogren's syndrome; sleep disturbance; spondyloarthropathies; systemic lupus erythematosus; temporal mandibular joint disease; thyroiditis; tissue transplantation; an inflammatory condition resulting from strain; an inflammatory condition resulting from sprain; an inflammatory condition resulting from cartilage damage; an inflammatory condition resulting from trauma; an inflammatory condition resulting from orthopedic surgery; an inflammatory condition resulting from infection; transplant rejection; uveitis; and vasculitis.

24 (Currently Amended). A method for modulating a T-helper cell mediated immune response in a patient in need thereof, which comprises administering to said patient an effective amount of an ~~IL-27R/WSX-1 ligand~~ IL-27R agonist.

25 (Previously Presented). The method of claim 24, wherein said T-helper cell is Th1.

26 (Previously Presented). The method of claim 24, wherein said T-helper cell is Th2.

27 – 72 (Cancelled)

73 (Currently Amended). The method of claim 1, wherein said ~~immune disorder is~~ patient suffers from a disorder selected from the group consisting of: Acquired Immune Deficiency Syndrome (AIDS); acute pancreatitis; Addison's disease; alcohol-induced liver injury; alcoholic cirrhosis; Alzheimer's disease; amyotrophic lateral sclerosis ~~amyelolaterosclerosis~~; asthma; pulmonary disease; atherosclerosis; autoimmune vasculitis; autoimmune hepatitis-induced hepatic injury; biliary cirrhosis; cachexia/anorexia; AIDS-induced cachexia; cancer; multiple myeloma; leukemia; myelogenous leukemias; tumor metastasis; chronic fatigue syndrome; Clostridium associated illnesses; Clostridium-associated diarrhea; a coronary condition; a coronary indication; congestive heart failure; coronary restenosis; myocardial infarction; myocardial dysfunction; a coronary artery bypass graft associated condition; diabetes; juvenile onset Type 1 diabetes; diabetes mellitus; insulin resistance; endometriosis; endometritis; an endometriosis/endometritis related condition; epididymitis; erythropoietin resistance; fever; fibromyalgia; analgesia; glomerulonephritis; graft versus host disease/transplant rejection; Graves' disease; Guillain-Barre syndrome; Hashimoto's disease; hemolytic anemia; hemorrhagic shock; hyperalgesia; inflammatory bowel disease; ulcerative colitis; Crohn's disease; an inflammatory conditions of a joint; rheumatic disease; osteoarthritis; rheumatoid arthritis; juvenile (rheumatoid) arthritis; seronegative polyarthritis; ankylosing spondylitis; Reiter's syndrome; reactive arthritis; Still's disease; psoriatic arthritis; enteropathic arthritis; polymyositis; dermatomyositis; scleroderma; systemic sclerosis; vasculitis; Kawasaki's disease; cerebral vasculitis; Lyme disease; staphylococcal-induced arthritis; Sjogren's syndrome; rheumatic fever; polychondritis; polymyalgia rheumatica; giant cell arteritis; inflammatory eye disease; corneal transplant associated inflammatory eye disease; inflammatory bowel disease; ischemia; cerebral ischemia; Kawasaki's disease; learning impairment; lung diseases; lupus

nephritis; multiple sclerosis; myasthenia gravis; myopathicneuroinflammatory disease; neurotoxicity; ocular diseases and conditions; ocular degeneration; uveitis; osteoporosis; pain; cancer-related pain; Parkinson's disease; pemphigus; periodontal disease; Pityriasis rubra pilaris; pre-term labor; prostatitis; a prostatitis related conditions; psoriasis; a psoriasis related condition; psoriatic arthritis; pulmonary fibrosis; reperfusion injury; rheumatic fever; rheumatoid arthritis; sarcoidosis; scleroderma; septic shock; side effects from radiation therapy; Sjogren's syndrome; sleep disturbance; spondyloarthropathies; systemic lupus erythematosus; temporal mandibular joint disease; thyroiditis; tissue transplantation; an inflammatory condition resulting from strain; an inflammatory condition resulting from sprain; an inflammatory condition resulting from cartilage damage; an inflammatory condition resulting from trauma; an inflammatory condition resulting from orthopedic surgery; an inflammatory condition resulting from infection; transplant rejection; uveitis; and vasculitis.